EICHORPublic-registry trials using SPY001 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
SPY001 appears in 1 registered trial Eichor's radar has found, sponsored by Spyre Therapeutics, Inc., the most recent registered as Phase 2, with a planned enrollment of 645. Registered timeline: 2025–2027. The registry holds 2,070 registered studies for Colitis.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Spyre Therapeutics, Inc. | Ulcerative Colitis | PHASE2 | 243 |
| Status | Recruiting · planned start 2025-05 |
| Primary completion | 2027-06 |
| Enrollment target | 645 participants |
| Design | Randomized · Parallel · Phase 2 · 13 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 259 listed in Argentina, Australia, Austria, Belgium |
All fields verbatim from the ClinicalTrials.gov record for NCT07012395.
| First registered study | June 2025 — NCT07012395 (Spyre Therapeutics, Inc.) |
| Registered studies matching this name | 2 all-time · 1 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 2,070 registered studies for Colitis. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Ulcerative Colitis drugs
← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs
